Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

BACKGROUND: Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS: In this phase 1 study involving patients with relapsed or refractory multiple myeloma, we...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :N Engl J Med
Главные авторы: Raje, Noopur, Berdeja, Jesus, Lin, Yi, Siegel, David, Jagannath, Sundar, Madduri, Deepu, Liedtke, Michaela, Rosenblatt, Jacalyn, Maus, Marcela V., Turka, Ashley, Lam, Lyh-Ping, Morgan, Richard A., Friedman, Kevin, Massaro, Monica, Wang, Julie, Russotti, Greg, Yang, Zhihong, Campbell, Timothy, Hege, Kristen, Petrocca, Fabio, Quigley, M. Travis, Munshi, Nikhil, Kochenderfer, James N.
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202968/
https://ncbi.nlm.nih.gov/pubmed/31042825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1817226
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы